Chris Mirabelli

Chris K.
Mirabelli is the founder of Ionis Pharmaceuticals, Inc., founded in 1989, where the title held was Senior Vice President-Research from 1989 to 1993.
Current jobs include Executive Chairman at Flamingo Therapeutics BV; Director at Theraclone Sciences, Inc., Galleon Pharmaceuticals, Inc., Visionary Therapeutics Corp., Fredonia College Foundation, and Guilford College (Trustee); Managing Director at Healthcare Partners VIII LLC, HealthCare Ventures LLC (since 2000), Healthcare Partners IX LLC, and Healthcare Strategic Partners, LLC; and Independent Director at Aro Biotherapeutics Co. (since 2020).
Former jobs include Chairman, President & Chief Executive Officer at LeukoSite, Inc. (1993–1999); Chief Executive Officer & Director at Anexon, Inc. (2012–2014); Chairman at Thios Pharmaceuticals, Inc. and Proteostasis Therapeutics, Inc. (2010–2016);.
Director, President-Pharmaceutical R&D at Millennium Pharmaceuticals, Inc. (1999–2000); Director at Critical Therapeutics, Inc. (2001–2008), FoldRx Pharmaceuticals LLC, Anchor Therapeutics, Inc., Antisoma, Inc., and Cypherpunk Technologies, Inc. (2025–2026); Independent Director at Trevena, Inc. (2013–2014); President & Director at DecImmune Therapeutics, Inc.; President at Adheron Therapeutics, Inc.; Principal at SmithKline & French SpA; and Member-Supervisory Board at Dynacure SA. Education includes an undergraduate degree from The State University of New York College at Fredonia in 1977 and a doctorate from Baylor College of Medicine in 1981.